Obesity

Showing NaN - NaN of 26

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Obesity Trial in United States (Cagrilintide, Semaglutide, Tirzepatide)

Not yet recruiting
  • Obesity
  • Birmingham, Alabama
  • +44 more
Nov 9, 2023

Overweight, Obesity and Diabetes, Type 2 Trial (Cagrilintide, Semaglutide, Placebo cagrilintide)

Not yet recruiting
  • Overweight
  • +2 more
  • Concord, California
  • +147 more
Jan 24, 2023

Obesity Trial (Cagrilintide, Semaglutide, Placebo cagrilintide)

Recruiting
  • Obesity
  • Birmingham, Alabama
  • +225 more
Jan 24, 2023

Obesity, Overweight Trial in Worldwide (Tirzepatide, Placebo)

Recruiting
  • Obesity
  • Overweight
  • Gilbert, Arizona
  • +695 more
Jan 18, 2023

Overweight, Obesity Trial in Worldwide (Semaglutide, Placebo (semaglutide))

Active, not recruiting
  • Overweight
  • Obesity
  • Birmingham, Alabama
  • +804 more
Dec 19, 2022

Obesity Trial in Worldwide (Placebo, PF-06882961)

Active, not recruiting
  • Obesity
  • Anniston, Alabama
  • +40 more
Jun 29, 2022

Obesity Trial in Worldwide (Semaglutide, Placebo (semaglutide))

Active, not recruiting
  • Obesity
  • Fairhope, Alabama
  • +97 more
Jun 15, 2022

Obesity, Overweight Trial in Worldwide (Tirzepatide, Placebo)

Active, not recruiting
  • Obesity
  • Overweight
  • Huntington Park, California
  • +64 more
Mar 22, 2022

Overweight, Obesity Trial in Worldwide (NNC0174-0833, Placebo (NNC0174-0833), Liraglutide 3.0 mg)

Completed
  • Overweight
  • Obesity
  • Anaheim, California
  • +53 more
Feb 24, 2022

Metabolism and Nutrition Disorder, Obesity Trial in Worldwide (Semaglutide, Placebo)

Completed
  • Metabolism and Nutrition Disorder
  • Obesity
  • Anniston, Alabama
  • +71 more
Jan 7, 2022

Obesity, Overweight Trial in Worldwide (Semaglutide 1.0 mg, Semaglutide 2.4 mg, Placebo I (Semaglutide))

Completed
  • Obesity
  • Overweight
  • Semaglutide 1.0 mg
  • +3 more
  • Buena Park, California
  • +146 more
Nov 8, 2021

Obesity, Surgery, Quality of Life Trial in United Kingdom (Gastric Band, Gastric Bypass, Sleeve Gastrectomy)

Recruiting
  • Obesity
  • +3 more
  • Gastric Band
  • +2 more
  • Birmingham, United Kingdom
  • +11 more
Oct 7, 2021

Metabolism and Nutrition Disorder, Obesity Trial in Worldwide (semaglutide, liraglutide, )

Completed
  • Metabolism and Nutrition Disorder
  • Obesity
  • Anaheim, California
  • +73 more
Apr 14, 2020

Obesity Trial in Worldwide (JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3)

Completed
  • Obesity
  • JNJ-64565111 Dose Level 1
  • +4 more
  • Phoenix, Arizona
  • +50 more
Jan 14, 2020

Cardiovascular Disease, High Cardiovascular Risk, Obesity Trial in Worldwide (Lorcaserin HCl, Placebo)

Completed
  • Cardiovascular Disease
  • +4 more
  • Lorcaserin hydrochloride
  • Placebo
  • Alexander City, Alabama
  • +498 more
Jun 27, 2019

Obesity Trial in United States (S-2367 Placebo, S-2367 800 mg, S-2367 1600 mg)

Completed
  • Obesity
  • S-2367 Placebo
  • +3 more
  • Mobile, Alabama
  • +37 more
May 8, 2018

Obesity Trial in United States (S-2367 (velneperit))

Completed
  • Obesity
  • S-2367 (velneperit)
  • Birmingham, Alabama
  • +72 more
Apr 26, 2018

Metabolism and Nutrition Disorder, Obesity Trial in Worldwide (liraglutide, )

Completed
  • Metabolism and Nutrition Disorder
  • Obesity
  • Birmingham, Alabama
  • +225 more
Dec 20, 2017

Metabolism and Nutrition Disorder, Obesity Trial in Worldwide (liraglutide, )

Completed
  • Metabolism and Nutrition Disorder
  • Obesity
  • Vestavia Hills, Alabama
  • +160 more
Dec 6, 2017

Obesity, Overweight Trial in United States (NB32, PBO, Weight Management Program)

Terminated
  • Obesity
  • Overweight
  • Birmingham, Alabama
  • +223 more
Feb 24, 2017

Obesity, Cardiovascular Diseases Trial in United States (Naltrexone HCl/Bupropion HCl ER, Placebo)

Terminated
  • Obesity
  • Cardiovascular Diseases
  • Naltrexone HCl/Bupropion HCl ER
  • Placebo
  • Alexander City, Alabama
  • +138 more
Feb 21, 2017

Obesity, Overweight Trial in United States (NB, CLI, Usual Care)

Completed
  • Obesity
  • Overweight
  • Denver, Colorado
  • +14 more
Nov 30, 2015

Obesity Trial in Worldwide (Placebo, CP-945,598, CP-945,598 Treatment B)

Terminated
  • Obesity
  • Placebo
  • +2 more
  • Birmingham, Alabama
  • +90 more
Nov 5, 2012

Obesity Trial in Canada, United States (CP-945,598 Treatment A, CP-945,598 Treatment B, Placebo)

Terminated
  • Obesity
  • CP-945,598 Treatment A
  • +2 more
  • Fairhope, Alabama
  • +81 more
Nov 5, 2012

European Study of Cardiovascular Risk

Completed
  • Cardiovascular Risk Factors
  • +5 more
    • Alland, Austria
    • +777 more
    Oct 28, 2009